Curocell, Inc.

The South Korea government plans to improve the transparency and objectivity of standards for pharma firms to officially qualify as “innovative” and eligible for special policy treatment, amid foreign

South Korean venture Curocell has filed for domestic regulatory approval of its next generation CD19-targeting drug Rimqarto (anbalcabtagene autoleucel or anbal-cel) for relapsed or refractory large B

South Korean bioventures looking for partners to help develop and launch their innovative modalities in the Japanese market, and potentially thereafter on the global stage, recently took part in an in

South Korean bioventures have experienced a harsh financing environment in 2023 stemming from economic depression, high interest rates and a general deterioration in investor sentiment. Although most